Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Checklist for Evaluation of Image-Based Artificial Intelligence Reports in Dermatology
143
Zitationen
19
Autoren
2021
Jahr
Abstract
IMPORTANCE: The use of artificial intelligence (AI) is accelerating in all aspects of medicine and has the potential to transform clinical care and dermatology workflows. However, to develop image-based algorithms for dermatology applications, comprehensive criteria establishing development and performance evaluation standards are required to ensure product fairness, reliability, and safety. OBJECTIVE: To consolidate limited existing literature with expert opinion to guide developers and reviewers of dermatology AI. EVIDENCE REVIEW: In this consensus statement, the 19 members of the International Skin Imaging Collaboration AI working group volunteered to provide a consensus statement. A systematic PubMed search was performed of English-language articles published between December 1, 2008, and August 24, 2021, for "artificial intelligence" and "reporting guidelines," as well as other pertinent studies identified by the expert panel. Factors that were viewed as critical to AI development and performance evaluation were included and underwent 2 rounds of electronic discussion to achieve consensus. FINDINGS: A checklist of items was developed that outlines best practices of image-based AI development and assessment in dermatology. CONCLUSIONS AND RELEVANCE: Clinically effective AI needs to be fair, reliable, and safe; this checklist of best practices will help both developers and reviewers achieve this goal.
Ähnliche Arbeiten
Dermatologist-level classification of skin cancer with deep neural networks
2017 · 13.436 Zit.
Tumor Angiogenesis: Therapeutic Implications
1971 · 10.108 Zit.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011 · 7.667 Zit.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · 5.803 Zit.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · 5.354 Zit.
Autoren
Institutionen
- Stanford Medicine(US)
- INESC TEC(PT)
- Instituto Superior Técnico(PT)
- The University of Queensland(AU)
- University of Central Arkansas(US)
- Conway School of Landscape Design(US)
- Microsoft (United States)(US)
- Hospital Clínic de Barcelona(ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer(ES)
- Universitat de Barcelona(ES)
- The University of Sydney(AU)
- Royal Prince Alfred Hospital(AU)
- Melanoma Institute Australia(AU)
- Emory University(US)
- Memorial Sloan Kettering Cancer Center(US)
- Kitware (United States)(US)
- Medical University of Vienna(AT)
- National and Kapodistrian University of Athens(GR)
- Vanderbilt University(US)
- VA Tennessee Valley Healthcare System(US)
- Vanderbilt University Medical Center(US)